Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Helyezés a részvények között
#4851
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Részvényárfolyam
$2.55
Piaci kapitalizáció
$3.05B
Változás (1 nap)
3.33%
Változás (1 év)
-11.84%
Ország
CN
Kereskedés Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategória
Healthcare
Jilin Aodong Pharmaceutical Group Co., Ltd. (000623) nyeresége
Nyereség ekkor: Jun 2026 TTM: $450.70M
Jilin Aodong Pharmaceutical Group Co., Ltd. legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $450.70M. 2023 évben a vállalat $211.93M nyereséget ért el, csökkenés a 2022 év nyereségéhez, amely $249.47M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Jilin Aodong Pharmaceutical Group Co., Ltd. nyereségtörténete 2000 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $450.70M | 116.23% |
| 2024 | $208.44M | -1.65% |
| 2023 | $211.93M | -15.05% |
| 2022 | $249.47M | -10.25% |
| 2021 | $277.96M | 5.78% |
| 2020 | $262.76M | 23.65% |
| 2019 | $212.51M | 47.80% |
| 2018 | $143.78M | -51.61% |
| 2017 | $297.11M | 18.54% |
| 2016 | $250.63M | -39.05% |
| 2015 | $411.21M | 71.49% |
| 2014 | $239.79M | 22.14% |
| 2013 | $196.32M | 79.35% |
| 2012 | $109.46M | -71.97% |
| 2011 | $390.52M | 99.92% |
| 2010 | $195.34M | -5.51% |
| 2009 | $206.72M | 55.20% |
| 2008 | $133.20M | -52.18% |
| 2007 | $278.56M | 315.81% |
| 2006 | $66.99M | 289.48% |
| 2005 | $17.20M | -21.22% |
| 2004 | $21.83M | 20.73% |
| 2003 | $18.09M | 43.68% |
| 2002 | $12.59M | 67.81% |
| 2001 | $7.50M | -36.78% |
| 2000 | $11.87M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 291.51% |
IN
|
